FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/06/069145 [Registered on: 19/06/2024] Trial Registered Prospectively
Last Modified On: 17/06/2024
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda 
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   Normal Delivery through Ayurveda  
Scientific Title of Study   A Randomized comparative clinical trial to evaluate the efficacy of Integrated and Ayurvedic protocol in achieving Sukhaprasava.  
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Jyoti Singh 
Designation  PG Scholar 
Affiliation  National Institute of Ayurveda Deemed to be University(De Novo), Jaipur 
Address  Department of Prasuti Tantra and Stri Roga, National Institute of Ayurveda, Deemed to be University(De Novo), Madhav Vilas Palace,Jorawar Singh Gate, Amer Road, Jaipur
National Institute of Ayurveda, Deemed to be University(De Novo), Madhav Vilas Palace, Jorawar Singh Gate, Amer Road, Jaipur
Jaipur
RAJASTHAN
302002
India 
Phone  9554767875  
Fax    
Email  dr.jyotisinghms@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Prof K Bharathi 
Designation  Professor and HOD 
Affiliation  National Institute of Ayurveda Deemed to be University(De Novo), Jaipur 
Address  Third Floor, Department of Prasuti Tantra and Stri Roga, National Institute of Ayurveda, Deemed to be University(De Novo), Madhav Vilas Palace,Jorawar Singh Gate, Amer Road, Jaipur
National Institute of Ayurveda, Deemed to be University(De Novo), Madhav Vilas Palace, Jorawar Singh Gate, Amer Road, Jaipur
Jaipur
RAJASTHAN
302002
India 
Phone  9492047131  
Fax    
Email  baruhunt@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Prof K Bharathi 
Designation  Professor and HOD 
Affiliation  National Institute of Ayurveda Deemed to be University(De Novo), Jaipur 
Address  Third Floor, Department of Prasuti Tantra and Stri Roga, National Institute of Ayurveda, Deemed to be University(De Novo), Madhav Vilas Palace,Jorawar Singh Gate, Amer Road, Jaipur
National Institute of Ayurveda, Deemed to be University(De Novo), Madhav Vilas Palace, Jorawar Singh Gate, Amer Road, Jaipur
Jaipur
RAJASTHAN
302002
India 
Phone  9492047131  
Fax    
Email  baruhunt@gmail.com  
 
Source of Monetary or Material Support  
Nageshwar Pharmacy, National Institute of Ayurveda Deemed To be University,Jorawar Singh Gate, Jaipur, Rajasthan, India(302002) 
 
Primary Sponsor  
Name  National Institute of Ayurveda Deemed To be University, Jaipur 
Address  Department of Prasuti Tantra and Stri Roga, National Institute of Ayurveda Deemed To be University(De Novo),Madhav Vilas Palace,Jorawar Singh Gate, Amer Road, Jaipur 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Jyoti Singh  National Institute of Ayurveda Deemed To be University, Jaipur  OPD No 26-27 and IPD of Prasuti Tantra and Stri Roga Department, National Institute of Ayurveda Deemed To be University(De Novo), Madhav Vilas Palace,Jorawar Singh Gate,Amer Road, Jaipur
Jaipur
RAJASTHAN 
9554767875

dr.jyotisinghms@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee, National Institute of Ayurveda Deemed to be University ,Jorawar Singh Gate,Jaipur,Rajasthan(302002)  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition:O80||Encounter for full-term uncomplicated delivery. Ayurveda Condition: GARBINIROGAH,  
 
Intervention / Comparator Agent  
snoIntervention/ComparatorTypeDrug-TypeProcedure NameDetails
1Comparator ArmProcedure-bastikarma/vastikarma, बस्तिकर्म/वस्तिकर्म (Procedure Reference: Charak Samhita, Procedure details: Kebuka Taila Yoni Pichu (Pichu size 3x3cm)- 37th week of gestation onwards, twice a week (min 2- max 8))
(1) Medicine Name: Bala Taila, Reference: Charak Samhita, Route: Rectal, Dosage Form: Taila, Dose: 60(ml), Frequency: sos, Duration: 4 Weeks
(2) Medicine Name: Dashmoola Kwath, Erand Taila, Reference: Charak Samhita, Route: Rectal, Dosage Form: Kwatha/Kashaya, Dose: 350(ml), Frequency: sos, Duration: 1 Days
(3) Medicine Name: Kebuka Taila, Reference: Sushrut Samhita, Route: Vaginal, Dosage Form: Taila, Dose: 10(ml), Frequency: sos, Duration: 4 Weeks
2Intervention ArmProcedure-bastikarma/vastikarma, बस्तिकर्म/वस्तिकर्म (Procedure Reference: Modern Medicine, Procedure details: Tab. Misoprostol-25ug, Sublingual, After onset of labor & before 5-6 cm cervical dilatation (Min 1 - max 4 times) )
(1) Medicine Name: Bala Taila, Reference: Charak Samhita, Route: Rectal, Dosage Form: Taila, Dose: 60(ml), Frequency: sos, Duration: 4 Weeks
(2) Medicine Name: Dashmoola Kwath, Erand Taila, Reference: Charak Samhita, Route: Rectal, Dosage Form: Kwatha/Kashaya, Dose: 350(ml), Frequency: sos, Duration: 1 Days
(3) Medicine Name: kebuka Taila, Reference: Database on medicine used in ayurveda volume 7,pg.208, Route: Vaginal, Dosage Form: Taila, Dose: 10(ml), Frequency: sos, Duration: 4 Weeks
(4) Medicine Name: Tab Misoprostol, Reference: Modern Medicine, Route: Oral, Dosage Form: Gutika/Vati/Ghana Vati/Tablets, Dose: 0.025(mg), Frequency: sos, Duration: 1 Days
 
Inclusion Criteria  
Age From  21.00 Year(s)
Age To  40.00 Year(s)
Gender  Female 
Details  1. Patient with 37th week of gestation with singleton pregnancy and cephalic presentation
2. Height 148 to 172cm
3. Hemoglobin more than or equal to 10gm%
4. Patient with borderline or adequate pelvis
 
 
ExclusionCriteria 
Details  1. History of previous LSCS
2. Patient having Bad obstetric history, precious pregnancy
3. Pregnancy associated with severe Pregnancy induced hypertension, Pre-eclampsia, Eclampsia, Gestational Diabetes, Placenta previa, Abruptio placentae, severe oligohydramnios, severe polyhydramnios, severe IUGR
4. Patients with Cephalo-pelvic disproportion, malpresentation.
5. Patients suffering with systemic disorders like Diabetes Mellitus, Renal dysfunction, Cardiac disorder, Tuberculosis, Coagulopathies.
6. Patients diagnosed with Benign or Malignant tumor of Reproductive system, Recto vaginal fistula, Vesico-vaginal fistula, second and third degree uterine prolapse
7. History of Fothergill repair, Recto vaginal fistula, Vesico-vaginal fistula
8. VDRL, HIV, HBsAg positive pregnant woman.
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Sukhaprasava (Normal Vaginal Delivery)   45 days 
 
Secondary Outcome  
Outcome  TimePoints 
• Differences in the incidence of complications of all four stages of labor and up to 10 days postpartum between the groups
• Differences in the rate of Sukhaprasava (Eutocia) & Shalyajanana (Caesarean section) between the groups
• Differences in the incidence of fetal distress between the groups
 
45 days 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2/ Phase 3 
Date of First Enrollment (India)   01/07/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Need of Study:

To decrease the utilization of oxytocic drugs in conduction of normal vaginal delivery.

Protracted cervical dilatation and unripe cervix are the leading causes of fetal distress and prolonged labor. Yoni Pichu application during 9th month brings optimum effacement and ripening of cervix as it causes hydration of tissues and remodeling of cervix.

Basti and Yoni Pichu increases uterine tone and avoid atonic PPH and reduce the rate of obstetric hysterectomy due to PPH.

Null Hypothesis: There is no difference between Integrated and Ayurvedic protocol in achieving Sukhaprasava.

Alternate hypothesis: There is difference between Integrated and Ayurvedic protocol in achieving Sukhaprasava.

Research Question: Is there any difference between Integrated and Ayurvedic protocol in achieving Sukhaprasava?

Aim: To evaluate and compare the efficacy of  Integrated and Ayurvedic protocol in achieving Sukhaprasava.

Primary Objective: To evaluate and compare the efficacy of  Integrated and Ayurvedic protocol in achieving Sukhaprasava.

Secondary Objective:

To access and compare the incidence of complications of all the four stages of labor and up to 10 days after delivery.

To access and compare the rate of Sukhaprasava (Eutocia) and Shalyajanana (Caesarean section)

To access and compare the incidence of fetal distress.

Drug Intervention: 

Two Group

Group MBP- Bala Taila Matra basti, Kebuka Taila Yoni Pichu, Asthapan Basti with Erand Taila and Dashmool Kwath, Tab Misoprostol.

Group BP- Bala Taila Matra basti, Kebuka Taila Yoni Pichu, Asthapan Basti with Erand Taila and Dashmool Kwath.






 
Close